
## **Gurmit Singh**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5390036/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Electrochemical sensing: A prognostic tool in the fight against COVID-19. TrAC - Trends in Analytical Chemistry, 2021, 136, 116198.	5.8	40
2	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. JAMA Network Open, 2021, 4, e216468.	2.8	111
3	Glutamate sensing in biofluids: recent advances and research challenges of electrochemical sensors. Analyst, The, 2020, 145, 321-347.	1.7	63
4	Sex differences in neuro(auto)immunity and chronic sciatic nerve pain. Biology of Sex Differences, 2020, 11, 62.	1.8	6
5	Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination. PLoS ONE, 2020, 15, e0234176.	1.1	23
6	Bone cancer-induced pain is associated with glutamate signalling in peripheral sensory neurons. Molecular Pain, 2020, 16, 174480692091153.	1.0	18
7	<p>Applying Serum Cytokine Levels to Predict Pain Severity in Cancer Patients</p> . Journal of Pain Research, 2020, Volume 13, 313-321.	0.8	13
8	Electrochemical Sensing of Cannabinoids in Biofluids: A Noninvasive Tool for Drug Detection. ACS Sensors, 2020, 5, 620-636.	4.0	50
9	Response to pregabalin and progesterone differs in male and female rat models of neuropathic and cancer pain. Canadian Journal of Pain, 2020, 4, 39-58.	0.6	7
10	An evaluation of the antiâ€hyperalgesic effects of cannabidiolic acidâ€methyl ester in a preclinical model of peripheral neuropathic pain. British Journal of Pharmacology, 2020, 177, 2712-2725.	2.7	20
11	Title is missing!. , 2020, 15, e0234176.		0
12	Title is missing!. , 2020, 15, e0234176.		0
13	Title is missing!. , 2020, 15, e0234176.		Ο
14	Title is missing!. , 2020, 15, e0234176.		0
15	<p>Effect of glutaminase inhibition on cancer-induced bone pain</p> . Breast Cancer: Targets and Therapy, 2019, Volume 11, 273-282.	1.0	3
16	Evaluating the efficacy of cannabidiol to manage surgically induced neuropathic pain in a preclinical rat model: Are T cells a sexually dimorphic target?. Canadian Journal of Pain, 2019, 3, 44-48.	0.6	1
17	<p>Activation of hippocampal microglia in a murine model of cancer-induced pain</p> . Journal of Pain Research, 2019, Volume 12, 1003-1016.	0.8	9
18	xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain. Molecular Pain, 2019, 15, 174480691882218.	1.0	17

#	Article	IF	CITATIONS
19	Inhibiting STAT3 in a murine model of human breast cancer-induced bone pain delays the onset of nociception. Molecular Pain, 2019, 15, 174480691882347.	1.0	7
20	Spinal microglia contribute to cancer-induced pain through system xC â^'-mediated glutamate release. Pain Reports, 2019, 4, e738.	1.4	4
21	Cancer pain and neuropathic pain are associated with A <b><i>β</i></b> sensory neuronal plasticity in dorsal root ganglia and abnormal sprouting in lumbar spinal cord. Molecular Pain, 2018, 14, 174480691881009.	1.0	17
22	Biological Mechanisms of Cancer-Induced Depression. Frontiers in Psychiatry, 2018, 9, 299.	1.3	54
23	Functional effects of TrkA inhibition on system x <sub>C</sub> <sup>â^'</sup> -mediated glutamate release and cancer-induced bone pain. Molecular Pain, 2018, 14, 174480691877646.	1.0	13
24	Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression. Scientific Reports, 2017, 7, 41382.	1.6	19
25	The complex roles of STAT3 and STAT5 in maintaining redox balance: Lessons from STAT-mediated xCT expression in cancer cells. Molecular and Cellular Endocrinology, 2017, 451, 40-52.	1.6	36
26	Rat model of cancer-induced bone pain: changes in nonnociceptive sensory neurons in vivo. Pain Reports, 2017, 2, e603.	1.4	12
27	ldentification of capsazepine as a novel inhibitor of system x <sub>c</sub> <sup>−</sup> and cancer-induced bone pain. Journal of Pain Research, 2017, Volume 10, 915-925.	0.8	19
28	Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways. Current Neuropharmacology, 2017, 15, 620-636.	1.4	13
29	Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity. PLoS ONE, 2016, 11, e0161202.	1.1	16
30	Differences in electrophysiological properties of functionally identified nociceptive sensory neurons in an animal model of cancer-induced bone pain. Molecular Pain, 2016, 12, 174480691662877.	1.0	18
31	Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS). Journal of Bone Oncology, 2016, 5, 57-62.	1.0	9
32	A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer. Journal of Bone Oncology, 2016, 5, 173-179.	1.0	15
33	<scp>RNA</scp> â€sequencing profiles hippocampal gene expression in a validated model of cancerâ€induced depression. Genes, Brain and Behavior, 2016, 15, 711-721.	1.1	10
34	Oncodynamic Effect of Cancer on Depression. , 2016, , 105-127.		0
35	The Disrupted Steady-State: Tipping the Balance in Favour of Cancer. , 2016, , 1-37.		0
36	Overview of Glutamatergic Dysregulation in Central Pathologies. Biomolecules, 2015, 5, 3112-3141.	1.8	87

#	Article	IF	CITATIONS
37	Depressive-like behaviours and decreased dendritic branching in the medial prefrontal cortex of mice with tumors: A novel validated model of cancer-induced depression. Behavioural Brain Research, 2015, 294, 25-35.	1.2	29
38	Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. Scientific Reports, 2015, 5, 8380.	1.6	42
39	Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells. Molecular and Cellular Biochemistry, 2015, 405, 205-221.	1.4	39
40	Expression of xCT and activity of system xcâ^ are regulated by NRF2 in human breast cancer cells in response to oxidative stress. Redox Biology, 2015, 5, 33-42.	3.9	188
41	AMP-activated protein kinase (AMPK) beyond metabolism. Cancer Biology and Therapy, 2014, 15, 156-169.	1.5	174
42	Mitochondrial FAD-linked Glycerol-3-phosphate Dehydrogenase: A Target for Cancer Therapeutics. Pharmaceuticals, 2014, 7, 192-206.	1.7	25
43	Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. Pain, 2014, 155, 28-36.	2.0	55
44	Cancer-Induced Oxidative Stress and Pain. Current Pain and Headache Reports, 2014, 18, 384.	1.3	15
45	The transcriptional responsiveness of LKB1 to STAT-mediated signaling is differentially modulated by prolactin in human breast cancer cells. BMC Cancer, 2014, 14, 415.	1.1	17
46	Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting. Journal of Bone Oncology, 2014, 3, 1-4.	1.0	5
47	Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers. Cancer & Metabolism, 2013, 1, 17.	2.4	37
48	Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer. Molecular Cancer, 2013, 12, 138.	7.9	36
49	Glutamate Signaling in Healthy and Diseased Bone. Frontiers in Endocrinology, 2012, 3, 89.	1.5	25
50	Liver kinase B1 expression (LKB1) is repressed by estrogen receptor alpha (ERα) in MCF-7 human breast cancer cells. Biochemical and Biophysical Research Communications, 2012, 417, 1063-1068.	1.0	24
51	Establishing a relationship between prolactin and altered fatty acid β-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer, 2011, 11, 56.	1.1	65
52	Ets-1 Regulates Energy Metabolism in Cancer Cells. PLoS ONE, 2010, 5, e13565.	1.1	49
53	Characterization of a rat model of metastatic prostate cancer bone pain. Journal of Pain Research, 2010, 3, 213.	0.8	21
54	Metronomic PDT and Cell Death Pathways. Methods in Molecular Biology, 2010, 635, 65-78.	0.4	24

#	Article	IF	CITATIONS
55	Mechanisms associated with mitochondrial-generated reactive oxygen species in cancerThis article is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease Canadian Journal of Physiology and Pharmacology, 2010, 88, 204-219.	0.7	54
56	Cancer cells release glutamate via the cystine/glutamate antiporter. Biochemical and Biophysical Research Communications, 2010, 391, 91-95.	1.0	61
57	A by-product of glutathione production in cancer cells may cause disruption in bone metabolic processesThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease Canadian Journal of Physiology and Pharmacology, 2010, 88, 197-203.	0.7	12
58	Extracellular glutamate alters mature osteoclast and osteoblast functions. Canadian Journal of Physiology and Pharmacology, 2010, 88, 929-936.	0.7	35
59	Cancer cell lines release glutamate into the extracellular environment. Clinical and Experimental Metastasis, 2009, 26, 781-787.	1.7	78
60	Increased expression of mitochondrial glycerophosphate dehydrogenase and antioxidant enzymes in prostate cancer cell lines/cancer. Free Radical Research, 2007, 41, 1116-1124.	1.5	31
61	In Vitro Induction of PDT Resistance in HT29, HT1376 and SK-N-MC Cells by Various Photosensitizers¶. Photochemistry and Photobiology, 2007, 73, 651-656.	1.3	2
62	Extreme Dark Cytotoxicity of Nile Blue A in Normal Human Fibroblasts¶. Photochemistry and Photobiology, 2007, 74, 707-711.	1.3	1
63	etsâ€l is transcriptionally upâ€regulated by H 2 O 2 via an antioxidant response element. FASEB Journal, 2005, 19, 2085-2087.	0.2	76
64	High activity of mitochondrial glycerophosphate dehydrogenase and glycerophosphate-dependent ROS production in prostate cancer cell lines. Biochemical and Biophysical Research Communications, 2005, 333, 1139-1145.	1.0	70
65	Alterations in Mitochondrial and Apoptosisâ€regulating Gene Expression in Photodynamic Therapyâ€resistant Variants of HT29 Colon Carcinoma Cells <sup>¶</sup> . Photochemistry and Photobiology, 2005, 81, 306-313.	1.3	6
66	Calculation of Singlet Oxygen Dose from Photosensitizer Fluorescence and Photobleaching During mTHPC Photodynamic Therapy of MLL Cells <sup>¶</sup> . Photochemistry and Photobiology, 2005, 81, 196-205.	1.3	9
67	Role of the transcription factor Ets-1 in cisplatin resistance. Molecular Cancer Therapeutics, 2004, 3, 823-32.	1.9	37
68	Up-regulation of Hsp27 Plays a Role in the Resistance of Human Colon Carcinoma HT29 Cells to Photooxidative Stress¶. Photochemistry and Photobiology, 2002, 76, 98-104.	1.3	2
69	Scavenging of Extracellular H2O2 by Catalase Inhibits the Proliferation of HER-2/Neu-transformed Rat-1 Fibroblasts through the Induction of a Stress Response. Journal of Biological Chemistry, 2001, 276, 9558-9564.	1.6	132
70	Pathophysiologic interactions in skeletal metastasis. Cancer, 2000, 88, 2912-2918.	2.0	80
71	Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. Clinical and Experimental Metastasis, 2000, 18, 463-470.	1.7	23
72	The Role of the p53 Tumor Suppressor in the Response of Human Cells to Photofrin-mediated Photodynamic Therapy. Photochemistry and Photobiology, 2000, 71, 201-210.	1.3	39

#	Article	IF	CITATIONS
73	Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene, 1999, 18, 1663-1676.	2.6	138
74	Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*). Cancer Chemotherapy and Pharmacology, 1996, 38, 245-253.	1.1	6
75	A quantitative model for spontaneous bone metastasis: evidence for a mitogenic effect of bone on Walker 256 cancer cells. Clinical and Experimental Metastasis, 1992, 10, 403-410.	1.7	27
76	Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Clinical and Experimental Metastasis, 1992, 10, 411-418.	1.7	35
77	Evidence for lack of mitochondrial DNA repair followingcis-dichlorodiammineplatinum treatment. Cancer Chemotherapy and Pharmacology, 1990, 26, 97-100.	1.1	36
78	Distinct genomic copy number in mitochondria of different mammalian organs. Journal of Cellular Physiology, 1990, 143, 160-164.	2.0	205
79	Differential Toxicity of Cis andTrans Isomers of Dichlorodiammineplatinum. Journal of Biochemical Toxicology, 1988, 3, 223-233.	0.5	21